摘要
目的:研究人尿激肽原酶(human urinary kallikrein,HUK)治疗急性脑梗死的临床效果及其与影响因素的相关性。方法:120例急性脑梗死患者,分为治疗组与对照组,每组各60例。根据病情给予两组患者相同的基础治疗,治疗组在此基础上给予HUK注射液0.15 PNA U(p-nitroaniline unit,相当于10 000国际单位)+生理盐水50 mL静脉泵入,1次/d,共21 d。治疗前后对两组患者进行神经功能缺损程度评分(NIHSS)并比较。根据急性缺血性脑卒中试验(the trialof org 10172 in acute stroke treatment,TOAST)、牛津郡社区卒中项目(oxforshire community stroke project,OCSP)分型标准对治疗组患者进行分型。结果:治疗21 d后,治疗组NIHSS评分低于对照组(P<0.05),临床总有效率(81.67%)高于对照组(51.67%)。糖尿病及TOAST分型与HUK临床疗效相关(P<0.01);其他因素如年龄、性别、高血压、心脏疾病、高脂血症、吸烟、饮酒、短暂性脑缺血发作(TIA)、进展性脑梗死、OCSP分型与治疗组临床疗效无明显相关性(P均>0.05)。非糖尿病患者及非心源性脑梗死患者使用HUK的临床疗效优于糖尿病患者及心源性脑梗死患者。结论:HUK对急性脑梗死的治疗有一定的临床效果;糖尿病及TOAST分型可能是HUK的临床疗效的影响因素。
Objective： To investigate the effect of human urinary kallikrein（HUK） on acute cerebral infarction and the relationship between the treatment result and influential factors.Methods： One hundred and twenty patients with acute cerebral infarction were enrolled in the randomized control trail.All patients were randomly divided into treatment group（n = 60） and control group（n = 60）.They were both treated by identical basis therapy.The patients in the treatment group were treated by syringe pumps of 0.15 PNA HUK diluted in 50 mL saline once per day for 21 days.The national institutes of health stroke scale（NIHSS） scores of two groups were analyzed before and after the treatment.All patients were classified according to the trial of org 10 172 in acute stroke treatment（TOAST） classification and oxforshire community stroke project（OCSP） classification.Results： Before treatment,there was no significant difference in the NIHSS scores between the two groups（P 0.05）.At the end of treatment,the NIHSS scores in both groups were significantly decreased（P 0.05）.Compared with the control group,the treatment group had lower NIHSS scores（P 0.05）.The efficacy in the treatment group（81.67%） was better than that in the control group（51.67%）.The differences between diabetes,TOAST classification and clinical results were significant（P 0.05）.Age,sex,hypertension,heart disease,hyperlipidemia,smoking,drinking alcohol,transient ischemic attack（TIA）,progressive cerebral infarction,and OCSP classification had no significant effects on clinical results（P 0.05）.The efficacy using HUK to patients without diabetes and non cardiac cerebral infarction was better than the patients with diabetes and cardiac cerebral infarction.Conclusion： HUK is an effective treatment for acute cerebral infarction,especially for acute cerebral infarction patients without diabetes and non cardiac cerebral infarction patients.
出处
《江苏大学学报（医学版）》
CAS
2013年第4期350-353,359,共5页
Journal of Jiangsu University：Medicine Edition
关键词
人尿激肽原酶
急性脑梗死
临床疗效
影响因素
human urinary kallikrein
cerebral infarction
efficacy
influencing factors
